Antibody cocktail shows promise in fight against corona

246

BLOOD from a couple who contracted SARS-CoV-2 in Wuhan, China, early in the outbreak has yielded potent antibodies that have neutralized the virus in the laboratory and protected animals from some effects of the infection. Researchers have also found that combining two of the antibodies may prevent the virus from developing resistance.
In January 2020, the couple traveled to Toronto, Canada, and developed what were among the earliest confirmed cases of Covid-19 in North America.
It can take years to isolate and develop antibodies as treatments, but a team drew on recent technological advances to accelerate the process. Before the pandemic, they developed a way to isolate antibodies and screen them for the ability to neutralize a virus, all within 78 days.
Spurred by the health emergency posed by Covid-19, they streamlined their technique further, until it took them just 35 days to isolate 70 monoclonal antibodies that neutralize SARS-CoV-2 from the couple’s blood samples. Each monoclonal antibody is produced by a different line of memory B cells — a type of immune cell that “remembers” a particular protein sequence of the virus.
After working with 40 of the most effective antibodies, the researchers conducted a second set of studies. In these, they narrowed the field to several antibodies that target a part of the coronavirus’ characteristic spikes that allows it to invade host cells.
Scientists call this area the receptor-binding domain. In SARS-CoV-2, it locks onto a receptor, called ACE2, on the outer membrane of human cells. An antibody that blocks the receptor-binding domain can, therefore, prevent the virus from entering cells and replicating.
Such an antibody could be produced in large quantities and injected into patients as a treatment. Alternately, a vaccine could provoke the immune system to produce the same antibody for itself, providing protection from future infection.
POSTPARTUM DEPRESSION IN WOMEN OF COLOR: Women of color are at a higher risk of experiencing postpartum depression than white women and less likely to receive the care they need. In this Special Feature, health disparities expert Prof. Tiffany Green helps us examine some of the reasons behind these inequalities. Postpartum depression (PPD) is a condition in which the new parent may experience persistent feelings of sadness, emptiness, low energy, anxiety, irritability, and poor sleep or appetite. PPD affects over 11% of women in USA, or 1 in 9 women. However, the condition does not affect all women equally.